Tissue factor pathway inhibitor: structure, biology and involvement in disease.
Review published in The Journal of pathology (2006)
Abstract
Tissue factor (TF)-initiated coagulation plays a significant role in the pathophysiology of many diseases, including cancer and inflammation. Tissue factor pathway inhibitor (TFPI) is a plasma Kunitz-type serine protease inhibitor, which modulates initiations of coagulation induced by TF. In a factor (F) Xa-dependent feedback system, TFPI binds directly and inhibits the TF-FVII/FVIIa complex. Normally, TFPI exists in plasma both as a full-length molecule and as variably carboxy-terminal truncated forms. TFPI also circulates in complex with plasma lipoproteins. The levels and the dual inhibitor effect of TFPI on FXa and TF-FVII/FVIIa complex offers insight into the mechanisms of various pathological conditions triggered by TF. The use of selective pharmacological inhibitors has become an indispensable tool in experimental haemostasis and thrombosis research. In vivo administration of recombinant TFPI (rTFPI) in an experimental animal model prevents thrombosis (and re-thrombosis after thrombolysis), reduces mortality from E. coli-induced-septic shock, prevents fibrin deposition on subendothelial human matrix and protects against disseminated intravascular coagulation (DIC). Thus, TFPI may play an important role in modulating TF-induced thrombogenesis and it may also provide a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In this review, we consider structural and biochemical aspects of the TFPI molecule and detail its inhibitory mechanisms and therapeutic implications in various disease conditions.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Tissue factor (TF)-initiated coagulation plays a significant role in the pathophysiology of many diseases, including cancer and inflammation. Tissue factor pathway inhibitor (TFPI) is a plasma Kunitz-type serine protease inhibitor, which modulates initiations of coagulation induced by TF.
Por qué esto importa para la hirudoterapia
This review explores the structural, biochemical, and therapeutic aspects of tissue factor pathway inhibitor (TFPI), a plasma Kunitz-type serine protease inhibitor that modulates tissue factor-induced coagulation. It highlights findings from experimental animal models showing that recombinant TFPI can prevent thrombosis, reduce mortality from septic shock, and protect against disseminated intravascular coagulation. While the text discusses a Kunitz-type inhibitor—a structural classification of certain protease inhibitors—it does not suggest any direct relevance to hirudotherapy or live leech application. The abstract focuses strictly on a human endogenous inhibitor and recombinant drug development, making no reference to leeches or the broader leech secretome.
Citación
Tissue factor pathway inhibitor: structure, biology and involvement in disease.
Lwaleed et al. · The Journal of pathology, 2006
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026